WO2012083170A1 - Composés antiviraux - Google Patents

Composés antiviraux Download PDF

Info

Publication number
WO2012083170A1
WO2012083170A1 PCT/US2011/065501 US2011065501W WO2012083170A1 WO 2012083170 A1 WO2012083170 A1 WO 2012083170A1 US 2011065501 W US2011065501 W US 2011065501W WO 2012083170 A1 WO2012083170 A1 WO 2012083170A1
Authority
WO
WIPO (PCT)
Prior art keywords
optionally substituted
independently
occurrence
carbocycle
membered
Prior art date
Application number
PCT/US2011/065501
Other languages
English (en)
Inventor
Allan C. Krueger
Warren M. Kati
William A. Carroll
John K. Pratt
Douglas K. Hutchinson
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Priority to MX2013006951A priority Critical patent/MX2013006951A/es
Priority to CN201180066574.3A priority patent/CN103354808B/zh
Priority to JP2013544826A priority patent/JP5906253B2/ja
Priority to EP11806100.1A priority patent/EP2651885A1/fr
Priority to CA2819894A priority patent/CA2819894A1/fr
Publication of WO2012083170A1 publication Critical patent/WO2012083170A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

La présente invention concerne des composés efficaces dans l'inhibition de la réplication du virus de l'hépatite C (« VHC »). Cette invention concerne en outre des procédés de production de tels composés, des compositions comprenant de tels composés, et des procédés d'utilisation de tels composés pour traiter une infection par le VHC.
PCT/US2011/065501 2010-12-16 2011-12-16 Composés antiviraux WO2012083170A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
MX2013006951A MX2013006951A (es) 2010-12-16 2011-12-16 Compuestos antivirales.
CN201180066574.3A CN103354808B (zh) 2010-12-16 2011-12-16 抗病毒化合物
JP2013544826A JP5906253B2 (ja) 2010-12-16 2011-12-16 抗ウイルス性化合物
EP11806100.1A EP2651885A1 (fr) 2010-12-16 2011-12-16 Composés antiviraux
CA2819894A CA2819894A1 (fr) 2010-12-16 2011-12-16 Composes antiviraux

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42390610P 2010-12-16 2010-12-16
US61/423,906 2010-12-16

Publications (1)

Publication Number Publication Date
WO2012083170A1 true WO2012083170A1 (fr) 2012-06-21

Family

ID=45464913

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/065501 WO2012083170A1 (fr) 2010-12-16 2011-12-16 Composés antiviraux

Country Status (6)

Country Link
EP (1) EP2651885A1 (fr)
JP (1) JP5906253B2 (fr)
CN (1) CN103354808B (fr)
CA (1) CA2819894A1 (fr)
MX (1) MX2013006951A (fr)
WO (1) WO2012083170A1 (fr)

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8541424B2 (en) 2008-12-23 2013-09-24 Abbott Laboratories Anti-viral compounds
US8546405B2 (en) 2008-12-23 2013-10-01 Abbott Laboratories Anti-viral compounds
EP2651923A1 (fr) * 2010-12-15 2013-10-23 Abbvie Inc. Composés anti-viraux
WO2015038596A1 (fr) 2013-09-11 2015-03-19 Emory University Compositions à base de nucléotide et de nucléoside et utilisations correspondantes
US9187496B2 (en) 2009-12-18 2015-11-17 Idenix Pharmaceuticals Llc 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors
US9278922B2 (en) 2009-04-15 2016-03-08 Abbvie Inc. Anti-viral compounds
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9340520B2 (en) 2011-02-07 2016-05-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9546160B2 (en) 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US9770439B2 (en) 2013-07-02 2017-09-26 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9775831B2 (en) 2013-07-17 2017-10-03 Bristol-Myers Squibb Company Combinations comprising biphenyl derivatives for use in the treatment of HCV
US9840481B2 (en) 2016-03-22 2017-12-12 Merck Sharp & Dohme Corp. Allosteric modulators of nicotinic acetylcholine receptors
US10118920B2 (en) 2015-04-20 2018-11-06 Cellcentric Ltd Isoxazolyl substituted benzimidazoles
US10428065B2 (en) 2015-04-20 2019-10-01 Cellcentric Ltd Isoxazolyl substituted imidazopyridines
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10653711B2 (en) 2015-08-26 2020-05-19 Janssen Pharmaceutica Nv 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors
US10898504B2 (en) 2016-03-10 2021-01-26 Janssen Pharmaceutica Nv Substituted nucleoside analogues for use as PRMT5 inhibitors
US11059850B2 (en) 2017-12-08 2021-07-13 Janssen Pharmaceutica Nv Spirobicyclic analogues
US11098062B2 (en) 2016-10-03 2021-08-24 Janssen Pharmaceutica Nv Monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as PRMT5 inhibitors
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
US11279970B2 (en) 2017-02-27 2022-03-22 Janssen Pharmaceutica Nv Use of biomarkers in identifying cancer patients that will be responsive to treatment with a PRMT5 inhibitor
US11571437B2 (en) 2019-06-06 2023-02-07 Janssen Pharmaceutica Nv Methods of treating cancer using PRMT5 inhibitors
US11691970B2 (en) 2017-11-24 2023-07-04 Janssen Pharmaceutica Nv Pyrazolopyridinone compounds

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104610332B (zh) * 2015-02-26 2019-11-08 成都安斯利生物医药有限公司 一种制备四氢呋喃-3-三氟硼酸钾的方法
CN104672261A (zh) * 2015-02-27 2015-06-03 成都安斯利生物医药有限公司 一种制备四氢呋喃-3-硼酸频呐醇酯的方法
CN104592278A (zh) * 2015-02-28 2015-05-06 成都安斯利生物医药有限公司 一种制备四氢吡喃-3-硼酸频呐醇酯的方法

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6703403B2 (en) 1995-06-29 2004-03-09 Abbott Laboratories Method for improving pharmacokinetics
WO2007144174A1 (fr) 2006-06-16 2007-12-21 Syngenta Participations Ag Dérivés d'éthényle carboxamide utilisés comme microbicides
WO2010065681A1 (fr) * 2008-12-03 2010-06-10 Presidio Pharmaceuticals, Inc. Inhibiteurs du virus de l'hépatite c de type ns5a
WO2010091413A1 (fr) * 2009-02-09 2010-08-12 Enanta Pharmaceuticals, Inc. Dérivés du dibenzimidazole liés
WO2010099527A1 (fr) * 2009-02-27 2010-09-02 Enanta Pharmaceuticals, Inc. Inhibiteurs du virus de l'hépatite c
WO2010117635A1 (fr) * 2009-03-30 2010-10-14 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
WO2010144646A2 (fr) * 2009-06-11 2010-12-16 Abbott Laboratories Composés antiviraux
WO2010148006A1 (fr) * 2009-06-16 2010-12-23 Enanta Pharmaceuticals, Inc. Inhibiteurs du virus de l'hépatite c

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
KR20050108420A (ko) * 2003-04-02 2005-11-16 베링거 인겔하임 인터내셔날 게엠베하 Ｃ형 간염 바이러스 프로테아제 억제제를 위한 약제학적조성물
DK1902017T3 (da) * 2005-06-24 2014-06-30 Biotron Ltd Antivirale acylguanidinforbindelser
EP1996184A4 (fr) * 2006-03-21 2010-09-22 Joyant Pharmaceuticals Inc Promoteurs d'apoptose de petites molécules
WO2010096462A1 (fr) * 2009-02-17 2010-08-26 Enanta Pharmaceuticals, Inc Dérivés du diimidazole lié
TWI476190B (zh) * 2009-03-30 2015-03-11 必治妥美雅史谷比公司 Ｃ型肝炎病毒抑制劑
TW201038559A (en) * 2009-04-09 2010-11-01 Bristol Myers Squibb Co Hepatitis C virus inhibitors
WO2011109037A1 (fr) * 2010-03-04 2011-09-09 Enanta Pharmaceuticals, Inc. Agents pharmaceutiques combinatoires au titre d'inhibiteurs de la réplication du vhc

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6703403B2 (en) 1995-06-29 2004-03-09 Abbott Laboratories Method for improving pharmacokinetics
WO2007144174A1 (fr) 2006-06-16 2007-12-21 Syngenta Participations Ag Dérivés d'éthényle carboxamide utilisés comme microbicides
WO2010065681A1 (fr) * 2008-12-03 2010-06-10 Presidio Pharmaceuticals, Inc. Inhibiteurs du virus de l'hépatite c de type ns5a
WO2010091413A1 (fr) * 2009-02-09 2010-08-12 Enanta Pharmaceuticals, Inc. Dérivés du dibenzimidazole liés
WO2010099527A1 (fr) * 2009-02-27 2010-09-02 Enanta Pharmaceuticals, Inc. Inhibiteurs du virus de l'hépatite c
WO2010117635A1 (fr) * 2009-03-30 2010-10-14 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
WO2010144646A2 (fr) * 2009-06-11 2010-12-16 Abbott Laboratories Composés antiviraux
US20100317568A1 (en) 2009-06-11 2010-12-16 Abbott Labaoratories Anti-Viral Compounds
US20110092415A1 (en) 2009-06-11 2011-04-21 Abbott Labaoratories Anti-Viral Compounds
US20110207699A1 (en) 2009-06-11 2011-08-25 Abbott Labaoratories Anti-Viral Compounds
WO2010148006A1 (fr) * 2009-06-16 2010-12-23 Enanta Pharmaceuticals, Inc. Inhibiteurs du virus de l'hépatite c

Non-Patent Citations (31)

* Cited by examiner, † Cited by third party
Title
"PHARMACEUTICAL DOSAGE FORMS", 1980, MARCEL DECKER
ADJABENG, J. ET AL., J. ORG. CHEM., vol. 69, 2004, pages 5082
ADJABENG, J. ET AL., ORG. LETT., vol. 5, 2003, pages 953
AM- CHEM INT ED ENG, 2005, pages 403 - 406
AUST. J CHEM., 1997, pages 149 - 152
BUNGARD, H.: "DESIGN OF PRODRUGS", 1985, ELSEVIER, pages: 7 - 9,21-24
CHARIFSON, P.S. ET AL., J. MED. CHEM., vol. 51, 2008, pages 5243 - 5263
G. ADJABENG ET AL., J. ORG. CHEM., vol. 69, 2004, pages 5082
G. ADJABENG ET AL., ORG. LETT., vol. 5, 2003, pages 953
GREENE; WUTS: "PROTECTIVE GROUPS IN ORGANIC SYNTHESIS(3rd ed.,)", 1999, JOHN WILEY & SONS
HARTWIG, J. F.: "Handbook of Organopalladium Chemistry for Organic Synthesis", 2002, WILEY-INTERSCIENCE, pages: 1051 - 1096
HELV. CHIM. ACTA, 2010, pages 17 - 24
HOOVER; JOHN E.: "REMINGTON'S PHARMACEUTICAL SCIENCES", 1975, MACK PUBLISHING CO.
I MED CHEM, 2008, pages 8077 - 8087
J MED. CHEM., 1976, pages 414 - 419
J. CHEM. SOC. CHEM. COMMUN., 1994, pages 2305 - 2306
J. ORG. CHEM., 1983, pages 4649 - 4658
J. ORG. CHEM., 1984, pages 269 - 276
J. ORG. CHEM., 1990, pages 4025 - 33
J. ORG. CHEM., 2002, pages 5993 - 6000
J. ORG. CHEM., 2007, pages 4616
JACQUES ET AL.: "ENANTIOMERS, RACEMATES, AND RESOLUTIONS", 1981, JOHN WILEY AND SONS
JIANG, L.; BUCHWALD, S. L.: "Metal-Catalyzed Cross-Coupling Reactions", 2004, WILEY-VCH, pages: 699 - 760
LOUIE ET AL., J. ORG. CHEM., 1997, pages 1268 - 1273
MUCI, A. R.; BUCHWALD, S. L., TOP. CURR. CHEM., vol. 219, 2002, pages 131 - 209
ORG. LETT., 1999, pages 1839 - 1842
ORG. LETT., 2009, pages 5450 - 5453
PENG, T.; YANG, D., ORGANIC LETT., vol. 12, 2010, pages 496 - 499
SUGAWARA, M. ET AL., J. AM. CHEM. SOC., vol. 119, 1997, pages 11986
SYNTHESIS, 1995, pages 1432 - 4
WOLFE; BUCHWALD, J ORG. CHEM., 1997, pages 1264 - 1267

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546405B2 (en) 2008-12-23 2013-10-01 Abbott Laboratories Anti-viral compounds
US8541424B2 (en) 2008-12-23 2013-09-24 Abbott Laboratories Anti-viral compounds
US9163017B2 (en) 2008-12-23 2015-10-20 Abbvie Inc. Anti-viral compounds
US9249138B2 (en) 2008-12-23 2016-02-02 Abbvie Inc. Anti-viral compounds
US9278922B2 (en) 2009-04-15 2016-03-08 Abbvie Inc. Anti-viral compounds
US9187496B2 (en) 2009-12-18 2015-11-17 Idenix Pharmaceuticals Llc 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors
EP2651923A1 (fr) * 2010-12-15 2013-10-23 Abbvie Inc. Composés anti-viraux
EP2651923A4 (fr) * 2010-12-15 2014-06-18 Abbvie Inc Composés anti-viraux
US9340520B2 (en) 2011-02-07 2016-05-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9546160B2 (en) 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US9770439B2 (en) 2013-07-02 2017-09-26 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9775831B2 (en) 2013-07-17 2017-10-03 Bristol-Myers Squibb Company Combinations comprising biphenyl derivatives for use in the treatment of HCV
WO2015038596A1 (fr) 2013-09-11 2015-03-19 Emory University Compositions à base de nucléotide et de nucléoside et utilisations correspondantes
EP4094767A1 (fr) 2013-09-11 2022-11-30 Emory University Compositions à base de nucléotide et de nucléoside et leur utilisations
US10428065B2 (en) 2015-04-20 2019-10-01 Cellcentric Ltd Isoxazolyl substituted imidazopyridines
US10118920B2 (en) 2015-04-20 2018-11-06 Cellcentric Ltd Isoxazolyl substituted benzimidazoles
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US11883367B2 (en) 2015-08-26 2024-01-30 Janssen Pharmaceutica Nv 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors
US10653711B2 (en) 2015-08-26 2020-05-19 Janssen Pharmaceutica Nv 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors
US11318157B2 (en) 2015-08-26 2022-05-03 Janssen Pharmaceutica Nv 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors
US10898504B2 (en) 2016-03-10 2021-01-26 Janssen Pharmaceutica Nv Substituted nucleoside analogues for use as PRMT5 inhibitors
US9926285B2 (en) 2016-03-22 2018-03-27 Merck Sharp & Dohme Corp. Allosteric modulators of nicotinic acetylcholine receptors
US9840481B2 (en) 2016-03-22 2017-12-12 Merck Sharp & Dohme Corp. Allosteric modulators of nicotinic acetylcholine receptors
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
US11098062B2 (en) 2016-10-03 2021-08-24 Janssen Pharmaceutica Nv Monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as PRMT5 inhibitors
US11279970B2 (en) 2017-02-27 2022-03-22 Janssen Pharmaceutica Nv Use of biomarkers in identifying cancer patients that will be responsive to treatment with a PRMT5 inhibitor
US11691970B2 (en) 2017-11-24 2023-07-04 Janssen Pharmaceutica Nv Pyrazolopyridinone compounds
US11059850B2 (en) 2017-12-08 2021-07-13 Janssen Pharmaceutica Nv Spirobicyclic analogues
US11702441B2 (en) 2017-12-08 2023-07-18 Janssen Pharmaceutica Nv Spirobicyclic analogues
US11571437B2 (en) 2019-06-06 2023-02-07 Janssen Pharmaceutica Nv Methods of treating cancer using PRMT5 inhibitors

Also Published As

Publication number Publication date
CA2819894A1 (fr) 2012-06-21
CN103354808B (zh) 2016-08-10
MX2013006951A (es) 2013-10-03
JP5906253B2 (ja) 2016-04-20
JP2014504296A (ja) 2014-02-20
CN103354808A (zh) 2013-10-16
EP2651885A1 (fr) 2013-10-23

Similar Documents

Publication Publication Date Title
US9394279B2 (en) Anti-viral compounds
JP5906253B2 (ja) 抗ウイルス性化合物
US10039754B2 (en) Anti-viral compounds
US8921514B2 (en) Anti-viral compounds
US20120115918A1 (en) Anti-Viral Compounds
JP6790202B2 (ja) 抗ウィルス化合物
AU2016238925B2 (en) Anti-viral compounds
AU2014203655B2 (en) Anti-viral compounds

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11806100

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2819894

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2013544826

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2013/006951

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2011806100

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2011806100

Country of ref document: EP